Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

L.A. McKeown

September 01, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Daily News

Kidney Events High in Older Patients After HF Hospitalization

L.A. McKeown

May 30, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Opinion CV Team Dispatch

November 2023 News Roundup

L.A. McKeown

November 01, 2023

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal Care Resumes

News Daily News

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

Michael O'Riordan

October 18, 2022

News Conference News EuroPCR 2022

Registry Data Hint at MACE Benefit With Renal Denervation

Michael O'Riordan

May 17, 2022

News Opinion CV Team Dispatch

January 2022 News Roundup

L.A. McKeown

January 01, 2022

News Conference News TCT 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

Todd Neale

November 04, 2021

News Opinion CV Team Dispatch

November 2021 News Roundup

L.A. McKeown

November 01, 2021

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Industry News

FDA strengthens warning on NSAID labels

July 10, 2015

Advertisement

September 2024 Dispatch for the CV Team

August 2024 Dispatch for the CV Team

Kidney Events High in Older Patients After HF Hospitalization

Top Endovascular News of 2023

November 2023 News Roundup

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

Reduction in BP Drives Treatment Preference for Hypertensive Patients

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

Registry Data Hint at MACE Benefit With Renal Denervation

January 2022 News Roundup

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

November 2021 News Roundup

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

FDA strengthens warning on NSAID labels

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content